Why Is Lurbinectedin Not Used in Pregnancy?
Lurbinectedin (brand name Zepzelca), an alkylating agent for small cell lung cancer, is classified as pregnancy category D by the FDA, indicating positive evidence of human fetal risk based on animal data and its mechanism. It causes embryo-fetal toxicity, including death, by damaging DNA in rapidly dividing fetal cells.[1][2]
Animal Studies on Fetal Effects
In rats and rabbits, lurbinectedin at doses about 0.03 times the human clinical exposure led to:
- Post-implantation loss and early embryo death.
- Decreased fetal weight and skeletal variations (e.g., reduced ossification in ribs, vertebrae).
- No teratogenic effects at low doses, but toxicity increased with exposure.[2][3]
Human Data and Risks
No adequate human studies exist due to ethical concerns. Limited case reports and post-marketing data show risks of fetal harm, including miscarriage and congenital anomalies if used during pregnancy. It readily crosses the placenta, mimicking effects seen in similar chemotherapies.[1][4]
Recommendations for Pregnant Patients
- Avoid use in pregnancy; females of reproductive potential must use effective contraception during treatment and for 6 months after the last dose.
- Males should use contraception for 4 months post-treatment.
- Verify pregnancy status before starting. If exposure occurs, discuss risks with an oncologist and consider pregnancy termination counseling.[1][2]
Mechanism Behind Developmental Harm
As a selective inhibitor of oncogenic transcription, lurbinectedin traps DNA-topoisomerase I complexes, causing DNA breaks. Fetal tissues with high cell turnover (e.g., neural tube, limbs, organs) are most vulnerable during organogenesis (weeks 3-8).[3][5]
What If Exposed Accidentally?
Immediate consultation with a teratogen information service (e.g., MotherToBaby) is advised. Monitoring may include ultrasounds for growth and anomalies, but outcomes vary by trimester and dose.[4]
Sources
[1]: Zepzelca Prescribing Information (FDA)
[2]: Drugs.com - Lurbinectedin Pregnancy
[3]: PubChem - Lurbinectedin Toxicology
[4]: MotherToBaby Fact Sheet
[5]: Clinical Pharmacology Review (FDA)